147 related articles for article (PubMed ID: 24880947)
1. Vaccines and melanoma.
Ott PA; Fritsch EF; Wu CJ; Dranoff G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):559-69. PubMed ID: 24880947
[TBL] [Abstract][Full Text] [Related]
2. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
3. Antitumor vaccines, immunotherapy and the immunological constant of rejection.
Wang E; Monaco A; MonsurrĂ³ V; Sabatino M; Pos Z; Uccellini L; Wang J; Worschech A; Stroncek DF; Marincola FM
IDrugs; 2009 May; 12(5):297-301. PubMed ID: 19431094
[TBL] [Abstract][Full Text] [Related]
4. Personal neoantigen cancer vaccines: The momentum builds.
Fritsch EF; Hacohen N; Wu CJ
Oncoimmunology; 2014; 3():e29311. PubMed ID: 25101225
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
[TBL] [Abstract][Full Text] [Related]
6. HLA-binding properties of tumor neoepitopes in humans.
Fritsch EF; Rajasagi M; Ott PA; Brusic V; Hacohen N; Wu CJ
Cancer Immunol Res; 2014 Jun; 2(6):522-9. PubMed ID: 24894089
[TBL] [Abstract][Full Text] [Related]
7. Melanoma vaccines: mixed past, promising future.
Ozao-Choy J; Lee DJ; Faries MB
Surg Clin North Am; 2014 Oct; 94(5):1017-30, viii. PubMed ID: 25245965
[TBL] [Abstract][Full Text] [Related]
8. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.
Rajasagi M; Shukla SA; Fritsch EF; Keskin DB; DeLuca D; Carmona E; Zhang W; Sougnez C; Cibulskis K; Sidney J; Stevenson K; Ritz J; Neuberg D; Brusic V; Gabriel S; Lander ES; Getz G; Hacohen N; Wu CJ
Blood; 2014 Jul; 124(3):453-62. PubMed ID: 24891321
[TBL] [Abstract][Full Text] [Related]
9. Immunogenic peptide discovery in cancer genomes.
Snyder A; Chan TA
Curr Opin Genet Dev; 2015 Feb; 30():7-16. PubMed ID: 25588790
[TBL] [Abstract][Full Text] [Related]
10. Current perspectives on immunotherapy.
Weber JS
Semin Oncol; 2014 Oct; 41 Suppl 5():S14-29. PubMed ID: 25438996
[TBL] [Abstract][Full Text] [Related]
11. Neoantigens in cancer immunotherapy.
Schumacher TN; Schreiber RD
Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
[TBL] [Abstract][Full Text] [Related]
12. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Lu YC; Yao X; Crystal JS; Li YF; El-Gamil M; Gross C; Davis L; Dudley ME; Yang JC; Samuels Y; Rosenberg SA; Robbins PF
Clin Cancer Res; 2014 Jul; 20(13):3401-10. PubMed ID: 24987109
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Rizvi NA; Hellmann MD; Snyder A; Kvistborg P; Makarov V; Havel JJ; Lee W; Yuan J; Wong P; Ho TS; Miller ML; Rekhtman N; Moreira AL; Ibrahim F; Bruggeman C; Gasmi B; Zappasodi R; Maeda Y; Sander C; Garon EB; Merghoub T; Wolchok JD; Schumacher TN; Chan TA
Science; 2015 Apr; 348(6230):124-8. PubMed ID: 25765070
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
[TBL] [Abstract][Full Text] [Related]
15. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic vaccines for cancer: an overview of clinical trials.
Melero I; Gaudernack G; Gerritsen W; Huber C; Parmiani G; Scholl S; Thatcher N; Wagstaff J; Zielinski C; Faulkner I; Mellstedt H
Nat Rev Clin Oncol; 2014 Sep; 11(9):509-24. PubMed ID: 25001465
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines.
Butterfield LH
BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
[TBL] [Abstract][Full Text] [Related]
18. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.
Zhu EF; Gai SA; Opel CF; Kwan BH; Surana R; Mihm MC; Kauke MJ; Moynihan KD; Angelini A; Williams RT; Stephan MT; Kim JS; Yaffe MB; Irvine DJ; Weiner LM; Dranoff G; Wittrup KD
Cancer Cell; 2015 Apr; 27(4):489-501. PubMed ID: 25873172
[TBL] [Abstract][Full Text] [Related]
19. Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines.
Goldberg JM; Fisher DE; Demetri GD; Neuberg D; Allsop SA; Fonseca C; Nakazaki Y; Nemer D; Raut CP; George S; Morgan JA; Wagner AJ; Freeman GJ; Ritz J; Lezcano C; Mihm M; Canning C; Hodi FS; Dranoff G
Clin Cancer Res; 2015 Jul; 21(14):3178-86. PubMed ID: 25805798
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]